BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Boehringer Ingelheim GmbH And AbGenomics Corporation Sign Worldwide Exclusive Collaboration And License Agreement To develop And Commercialize A Therapeutic Monoclonal Antibody


10/19/2005 5:09:20 PM

Ingelheim/Germany and Taipei/Taiwan, 6 June 2005 - Boehringer Ingelheim International GmbH and AbGenomics Corporation announced today that they have signed an exclusive licensing agreement providing Boehringer Ingelheim with the worldwide exclusive rights to develop, manufacture and commercialize any products with AbGenomics Corporation’s antibody 168. Based on data generated by AbGenomics Corporation, antibody 168 may potentially be developed to treat a broad range of immune-related diseases. The initial focus of the development will be on therapies for autoimmune diseases. Specific terms of the transaction were not disclosed but they are comparable to the average licensing deals for compound of a similar stage and market potential. Also, AbGenomics Corporation has an option to co-promote in selected Asian countries. “Monoclonal antibodies are an increasingly important component of medical treatments. AbGenomics Corporation’s antibody 168, with its novel mechanism of action, has the potential of introducing a new therapeutic paradigm for the treatment of autoimmune diseases. Our agreement with AbGenomics Corporation is the latest example of our corporate strategy to build long-term growth by focusing on biopharmaceuticals and on potential disease areas with unmet medical needs.” said Dr Andreas Barner Vice Chairman of the Board Corporate Division Pharma Research, Development and Medicine at Boehringer Ingelheim.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES